Thomas Hielscher

Thomas Hielscher

Thomas Hielscher

Position:

Scientist

Phone:

+49 6221 42 2386

Fax:

+49 6221 42 2397

Building:

TP 4

Room:

S4.227

Area of Work

Analysis of prospective and retrospective studies, high-dimensional genomic data, survival data, clinical trials

Education and Background

  • DKFZ/Biostatistics since May 2007
  • 2004-2007 clinical trial statistician in pharmaceutical industry
  • Diploma, Statistics, University of Dortmund, 2004

Selected Publications

  1. Merz M, Hielscher T, Wagner B, Sauer S,  Shah S, Raab MS, Jauch A,  Neben K,  Hose D,  Egerer G, Weber MA,  Delorme S, Goldschmidt H, Hillengass J: Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia doi:10.1038/leu.2014.75; accepted, 2014.
  2. Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D: Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load. Journal of Clinical Oncology 31 (34), 4325-4332, 2013.
  3. Remke M*, Hielscher T*, Korshunov A, Northcott PA, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schoettler A  von Bueren AO, von Deimling A, Rutkowski S, Scheurlen W , Kulozik AE, Taylor MD, Lichter P, Pfister SM.: FSTL5 is a marker of poor prognosis in non-WNT/ non-SHH medulloblastoma. Journal of Clinical Oncology 29 (29), 3852-3861, 2011. (*joint first authors)
  4. Hielscher T*, Zucknick M*, Werft W, Benner A: On the prognostic value of survival models with application to gene expression signatures. Statistics in Medicine 29 (7-8), 818-829, 2010. (*joint first authors)
  5. Benner A, Zucknick M , Hielscher T, Ittrich C, Mansmann U: High-Dimensional Cox Models: The Choice of Penalty as Part of the Model Building Process. Biometrical Journal 52 (1), 50-69, 2010.

PubMed

Google Scholar

to top